Literature DB >> 26254264

Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?

Jason Grebely1, Bridget Haire2, Lynn E Taylor3, Paul Macneill4, Alain H Litwin5, Tracy Swan6, Jude Byrne7, Jules Levin8, Philip Bruggmann9, Gregory J Dore2.   

Abstract

Entities:  

Keywords:  Adherence; Drug users; HCV; IFN-free; Injecting; Injection; PWID

Mesh：

Substances：

Year:  2015        PMID： 26254264      PMCID： PMC6132058          DOI： 10.1016/j.jhep.2015.06.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  28 in total

Review 1.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Authors:  Jacob Lalezari; J Greg Sullivan; Peter Varunok; Edward Galen; Kris V Kowdley; Vinod Rustgi; Humberto Aguilar; Franco Felizarta; Barbara McGovern; Martin King; Akshanth R Polepally; Daniel E Cohen
Journal:  J Hepatol       Date:  2015-04-01       Impact factor: 25.083

Review 3.  Hepatitis C treatment for injection drug users: a review of the available evidence.

Authors:  Margaret Hellard; Rachel Sacks-Davis; Judy Gold
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

Review 4.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

5.  Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population.

Authors:  Adriaan J van der Meer; Heiner Wedemeyer; Jordan J Feld; Jean-François Dufour; Stefan Zeuzem; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

6.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

7.  Sticker shock and the price of new therapies for hepatitis C: is it worth it?

Authors:  Nancy S Reau; Donald M Jensen
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

Review 8.  What is killing people with hepatitis C virus infection?

Authors:  Jason Grebely; Gregory J Dore
Journal:  Semin Liver Dis       Date:  2011-12-21       Impact factor: 6.115

9.  Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.

Authors:  Bhupinder S Anand; Sue Currie; Eric Dieperink; Edmund J Bini; Hui Shen; Samuel B Ho; Teresa Wright
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

Review 10.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Authors:  Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079
View more
  21 in total

1.  Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.

Authors:  J Grebely; A Litwin; G J Dore
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

2.  Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles.

Authors:  Daniel Fuster; Lillian Gelberg
Journal:  J Community Health       Date:  2019-12

Review 3.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

4.  Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.

Authors:  Denis Ouzan; Dominique Larrey; Dominique Guyader; André-Jean Remy; Ghassan Riachi; Fréderic Heluwaert; Régine Truchi; Jean-Marc Combis; François Bailly; Isabelle Rosa; Christophe Hézode; Denise Glorian-Petraud; Olivier Libert; Heribert Ramroth; Tarik Asselah; Gérard Thiefin; Dominique Roulot; Bruno Roche; Vincent Leroy; Jérôme Dumortier; Dominique Thabut; Stanislas Pol
Journal:  Dig Dis Sci       Date:  2020-04-18       Impact factor: 3.199

5.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

6.  Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.

Authors:  Charitha Gowda; Vincent Lo Re
Journal:  Curr Hepatol Rep       Date:  2018-03-24

Review 7.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

8.  The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C.

Authors:  Nicholas van Buuren; Lorraine Fradette; Jason Grebely; Alexandra King; Mel Krajden; Sonya A MacParland; Alison Marshall; Sahar Saeed; Joyce Wilson; Marina B Klein; Selena M Sagan
Journal:  Can J Gastroenterol Hepatol       Date:  2016-10-24

Review 9.  Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections.

Authors:  Daniel Fuster; Arantza Sanvisens; Ferran Bolao; Inmaculada Rivas; Jordi Tor; Robert Muga
Journal:  World J Hepatol       Date:  2016-11-08

10.  A descriptive analysis of concurrent alcohol and substance use among patients living with HIV/HCV co-infection.

Authors:  Omar T Sims; Kaiying Wang; Rasheeta Chandler; Pamela A Melton; Duong N Truong
Journal:  Soc Work Health Care       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.